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Coletsos medium. 
Dlstribunon of porinve culture accordmg to the medm 
~~ 
both meda + Col + MGIT- Col - MGIT+ 
M. tubmubrir (n = 135) 64 27 
M. ovium (n = 29) 8 1 
M .  godome (n = 48) 3 20 
Others (n = 18) 2 10 






50.6% of mycobacteria were isolated before 30 days of incubation 
with MGIT, 47.4% with Coletsos medium. 
Conclusions: MGIT medium was more sensitive than Coletsos 
medium but the combination with a solid medium seems very useful 
to optimize the recovery of mycobacteria. Difference in time for 
growth detection was weak for M. tubernrlosis but more important 
for M. avium. 
Ip6911 Utilii of Adenosine Deaminase Activity in 
E. Vidal l ,  MJ. Cuesta ', E. Nuiio ', I. Suarez ', J.L. Sampedro ', 
R. Luque6, M. Gonzalez7, J. Miram6n8, L. Rodriguez', 
S. Gonzalez lo, A. Corrales ", F! Martin 12, J. Marin 13, A. Villar 14, 
J. Galvarro j5  for the Community Hospitals of Andalusia (Spain). 
Cabra, Spain, 'Jerez, Spain, Velez-Mhlaga, Spain, 4Huelva, Spain, 
'Linares, Spain, 6Mofril, Spain, 7La Linea, Spain, 'Ronda, Spain, 
g ~ ~ z ~ b ~ ~ ~ ,  Spain, "Algen'ras, Spain, "Baza,  Spain, "Marbella, 
Spain, '30suna, Spain, I 4  Ubeda, Spain, '5Riofinto, Spain 
The adenosine deaminase activity (ADA) in CSF was found usell to 
separate tuberculous meningitis (TM) of the other aseptic meningitis 
(AM). 
Objective: To evaluate the utility of ADA in differential diagnosis 
of AM. 
Setting: 15 community-based hospitals without neurologie de- 
partment h m  Andalusia. 
Methods: we studied 103 adults (77 men and 26 women) with 
meningitis of different etiologies: 18 pyogenic meningitis (PM), 25 
TM, 7 criptococcous meningitis (CM), 38 lymphocitic meningitis 
(LM) and 15 indeterminate meningitis (MI) [defined by neutrophilic 
pleocytosis and normal glucosa in CSF]. 25 patients were HIV (15 
TM, 8 CM, 2 LM, 1 MI). 
Results: The mean ADA level, range and sigdcance of compar- 
ison between TM ADA mean and other meningitis (P) are shown in 
TABLE 1. For a cutoff point of 512 UI/l, ADA level has: 1) a sensi- 
tivity of 84% and a specificity of 89.5%; 2) a positive predictive value 
(PPV) of 87.5% and a negative predictive value ("V) of 89.7% as 
criterion of TM vs LM; and 3) a PPV of 91.3% and a NPV of 76.4% 
for TM vs MI. 
Aseptic Meningitis 
No mean nnw P 
PM 18 10.67 1-50 0.009 
TM 25 23.28 2-73 
CM 7 15.57 2-50 0.1442 
LM 38 5.10 1-23 O.oOo0 
IM 15 9.07 1-58 0.0004 
Conclusion: ADA level 212 UI/l was a useful test for to disM- 
guish TM h m  the other AM, but a low ADA level not exclude the 
TM diagnostic. 
New Betalactams 
In vitm Activity of Cefepime against 
Multiresistant Nosocomial Gram-negative 
Bacteria 
J. Blahovi, V KrZmCry, K. Kr;ilikovi. Imt. ofReventive and Clin. 
Med., Bratislava, Slovakia 
Objectives: Cefepime @MY 28142, Bristol-Meyea Squibb) is 
classified as the "fourth generation" cephalosporin. We tested the 
in vitro activity of cefepime against 89 cefotaxime- and cef- 
tazidime-resistant isolates of "problematic" bacteria (Stenofrophomonas 
maltophilia, Flavobacterium meningosepfinrm, Mebsiella pneumoniae, Sph- 
ingobacterium mulfivomm, Pseudomonas amginosa, Enterobacter c l o u e ,  
Acinefobacter baumanii, Burkholdm'a cepan'a). Bacterial strains used in 
this study were dinical isolates from various hospitals. Strains were 
resistant to 25 pg/ml and more of ceftazidune. 
Methods: MIC(s) were determined by an agar dilution method 
with 2-fold dtlutions of antibiotics. To visualise the presence of ESBL 
in strains,  double-disk Husion test was used. Transfer of antibiotic 
resistance in liquid cultures was performed as described by Knothe 
et al. (1983). 
Results: From 30 S. maltophilia, E meningosepficum and Sph. mul- 
tivonrm s t r a i n s  naturally resistant to imipenem, 26 were susceptible 
to cefepime with MIC in range 3.13-6.25 ,ug/ml. Four S. mal- 
tophilia and 2 of 22 I? aemginosa strains had MIC = 12.5 p g / d  and 
were considered resistant. Transferable resistance to cefotaxime and 
ceftazidune and double-disk a s i o n  test demonstrated the pres- 
ence of ESBL in the majority of K. pneumoniae, E .  cloacae and A. 
baumanii strains tested. MIC(s) of these strains were 1.56-6.25 of 
p g / d  of cefepime, i.e. cefepime is less a€fected by plasmid-mediated 
p-lactamases than ceftazidime and cefotaxime. 
Conclusions: Cefepime showed higher activity than ceftazidime 
with MIC in range 3.13-12.5 pg/ml in all strains tested. 
Comparative Activii of Cefepime Against 
Respiratory Pathogens of I? aemginosa A. 
baumanii, and Enterics from ICU Patients 
K.E. Aldridge', D. Ashcrafl', M. Gelfand'. 'LSUMedical  C e n f q  
New Orleans, LA, U S A ,  'Mefhodist Hospital, Memphis, TN U S A  
Continuing increased rates of resistance to broad-spectrum p-lactams 
is predominantly due to extended spectrum p-lactamases. Ce- 
fepime, a new fourth generation alpha-methoximino aminothiazolyl 
cephalosporin, has been shown to be stable to many ESBLS and 
because it is a zwitterion may penetrate most bacterial isolates to a 
greater degree. 
Objectives: To compare the in vim activity of cefepime to that 
of other antimicroblals against I? aeruginosa, A.  baumanii, and En- 
terobacteriaceae strains isolated h m  respiratory pathogens h m  ICU 
patients. 
Methods: Each isolate was tested to the various antimicrobials us- 
ing an NCCLS broth microdilution method. A total of 122 nondu- 
plicate strains were tested. 
Results: Agdlnst enteric isolates (all B-lactamase producers) ce- 
fepime was the most active antimicrobial tested with a mode MIC 
and MI& of 0.03 pg/ml and MIC" of 0.25 pg/ml. By com- 
parison cefepime was 4-fold more active than ofloxacin, gentarr- 
icin, and TMP/SMZ; 16- to 128-fold more active than cefeiaxone, 
ceftazidime, and imipenem; and 64- to 512-fold more active than 
B-lactamase inhibitor combinations. Against I? amginosa cefepime 
had comparable activity to ceftazidime, was 4-fold more active than 
imipenem and ampi&/sulbactam, and 8- to 16-fold more ac- 
tive than cefiriaxone and ticarcillin/clavulanate. Agamst A. baumanii 
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cefepime was active against 70% of s t r a i n s  compared to 25% for cef- 
triaxone, 14% for ceftazldime, 45% for piperacillin/tazobactam, 16% 
for ofloxacin, 12% for gentamicin, and 14% for TMP/SMZ. 
Conclusions: These data illustrate the increased spectrum of ac- 
tivity of cefepime against multi-resistant, respiratory isolates &om 
ICU patients. 
I P694 I Cefepime Activity against Pseudomonas 
aemginosa 
D. Talon, M. Thouverez, B. M&. Unifi d'Hygitne HospitaliPre, 
HSpital Jean Minjor, Besangon, France 
Objective: To rank B-lactam antibiotics such that the most appro- 
priate treatment regimens could be selected for Pseudomom m g i -  
nosa infections. 
Methods: The MICs of B-lactam antibiotics were determined by 
the Kirby-Bauer method and susceptible strains were defined accord- 
ing recommendations of USA NCCLS and of ComitC Franpis de 
YAntibiogramme (CFA). The phenotypes were defined on in viho 
susceptibility to ticarcillin, aztreonam, ceftazidime and imipenem. 
The index of absence of cross-resistance (ACR) was calculated for 
each resistant strain by subtracting the log2 of MIC of cefepime &om 
that of the other B-lactam antibiotic then calculating the mean index 
for all the strains.  
Resulw. The rates of susceptibility for the 386 isolates were: 
80.8% for cefepime (FEP), 78.8% for imipenem (IMP) and 75.4% 
for ceftazidime (CAZ) according NCCLS and 78.8% for imipenem, 
74.4% for ceftazidime and 64% for cefepime according CFA. 26.6% 
of the strains belonged to phenotype SSSS (A), 8.6% to pheno- 
type SSSR (B), 32.1% to phenotype SRSS or IRSS (C), 24% to 
RSRS (D), and 8.7% to other phenotypes. Table show indices for 
the absence of cross-resistance between cefepime and other B-lactam 
antibiotics/phenotype: 
A B C D Au 
CAZ 0.41 2.95 0.03 2.17 0.08 
IMP 3.08 1.89 2.43 1.52 1.47 
Conclusion: Cefepime was an active antibiotic on Pseudomonas 
aemginosa. The ACR index calculated for each phenotype show 
that there is a low cross-resistance index between ceftazidime and 
cefepime for phenotypes B and D. 
I P695 I Inhibitory In Viro Activii of Fourth-Generation 
Cephalosporins Against Highly Resistant 
Pseudomonas aemginosa Strains 
C. Tympanidou, A. Tsitsika, E.J. Giamarellos-Bourboulis, 
H. Giamarellou. I" Dept. Prop Med., Athens Medicnl School, Greece 
Objective: To evaluate the in vitro activity of cefepime, cefpirome 
and the newer KO37 (cefoselis) against multiresistant I! amginom 
strains, in comparison with that of 12 antipseudomonal antimicro- 
bials. 
Methods: The minimum inhibitory concentration (MIC) was 
determined for 94 I! amginosa strains, using a microdilution tech- 
nique after preparing a log-phase inoculum with a final concentra- 
tion of 5 x lo5 &I/&. 
Results: Having 8 g g / d  as a brekpoint, cefepime, cefpimme 
and KO37 lnhibited 24.5, 15.9 and 24.5% ofthe isolates respectively, 
while MIC5o-MIC9o were 32-128, 32-1256 and 32-2256wg/d 
respectively. Ceftazidune, piperacillin, imipenem, amikacin, ticar- 
c i h  + davulanate, aztreonam, gentamicin, carbenicillin, ticarcillin, 
netilmicin, tobramicin and ciprofloxacin were found active against 
46.2,34, 25.5, 21.3, 14.9, 12.8, 11.7, 10.6, 10.6, 10.6, 9.6 and7.5% 
of the isolates respectively. 
Conclusions: Fourth-generation cephalosporins agents have sim- 
ilar in vitro activity against 25% of I! m g i n o s a  multimistant strains, 
and they should not be administered empirically in hospitals with 
high resistant settings. 
lp6961 In Vim Activii of Modem Broadspectrum 
Antimicrobial Agents against Gramnegative 
Blood Culture Isolates 
H. Seifert. Institutfir Medirinische Mikrobiologie und Hygiene, 
University, Cologne, Germany 
We determined the in vitro activity of six broadspectrum antimi- 
crobials against 296 gram-negative pathogens isolated consecutively 
&om blood cultures of patients hospitalized in 1995. The speaes 
included were: E. coli (n = 137), Mebsiella spp. (42), I! aeruginosa 
(28), Enterobder spp. (27), Acinetobacter spp. (26), Proteus spp. (16), 
S.marcescetu (13). S. maltophilia (7). Susceptibility testing was per- 
formed by agar dilution accordmg to DIN guidelines. The antibi- 
otics tested were cefotaxime (CTX), ceftazidune (CAZ), cefepime 
(FEP), pipera&/tazobactam (PIP/TAZ), meropenem (MEP), and 
ciprofloxacin (CIP). 
Results: Percent of strains fully susceptible at DIN breakpoints 
(%) 
CTX CAZ FEP PIPITAZ MEP CIP 
BrclkpolntpIN) 2mgA 4mg/l 4mg/l 4mgA 4mg/l* Img/ l  
15 46 77 - 
100 100 100 97 
82 85 96 63 
86 93 98 76 
100 100 100 100 
0 100 71 54 
54 92 100 46 


















Among betalactam antibiotics, CAZ, FEE and MEP were the 
most active agents. E. uli was 100% susceptible to all tested antibi- 
otics except PIP/TAZ (97%) and CIP (96%). MEP and FEP were 
most active against Enterobacfq Mebsiella and Serratia spp, whereas 
CAZ was more active than the other antimicrobials tested against I! 
aemginosa. 
I P697 I Activity of Cefepime, Third Generation 
Cephalosporins, Imipenem, and Ciprofloxacin 
Against Extended Spectrum Beta-lactamase 
{ESBL)-Producing Strains of Klebsielh 
pneumoniae (Kp) Deficient or not in Porins 
L. Martinez-Martinez'.2, S. Hernindez-AU6s ', A.I. S&z ', 
VJ. Benedi3, A. Pasc~al'.~. 'Dpt. OfMimobiology, School OfMedicine, 
Spain, Uniu. Hosp. K Macarem, Swille, Spain, 3Ana Minobiologia, 
Dpto. Biol. Ambiental, Univ. I. Baleares, Palma de Malbrca, Spain 
Objectives: To evaluate the role of ESBL and porins in the in vim 
activity of six antimicrobial agents against clinical isolates of Kp. 
Methods: The activity of cefepime (CPM), cefotaxime (CTX), 
cefh-iaxone (CRX), ceftazidime (CAZ), imipenem (IMP), and 
ciprofloxacin (CIP) against 68 ESBL-producing climcal saains of Kp 
was evaluated by microdilution. Porin expression was determined by 
polyacrylamide gel electrophoresis of outer membrane proteins. 
Results: Eighteen strains lacked the two porins of Kp, and were 
categorized as porin-deficient. MIC values (rng/L) for 50% (MICso) 
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and 90% (MIC90) of the strains producing (P+, n = 50) or not 
producing (P-, n = 18) porins were as follows: 
Anumicrohd MIC5n MIC9n 
P+ P- P+ P- 
CPM 4 64 64 256 
CTX 16 128 128 > 256 
CRX 32 256 > 256 > 256 
CAZ 256 512 > 512 > 512 
IMP 0.125 0.25 0.5 1 
CIP 8 4 16 8 
Conclusions: IMP was the most active ofthe six agents evaluated, 
its activity being minimally dected by loss of porins. Loss of porins 
increased MIC values of the cephalosporins evaluated. CPM was the 
more active cephalosporin evaluated, in both P+ and P- strains. 
lp698/ In Viiro Activity of Carbapenem vs 
Amoxicillin/Clavulanic Acid against Hospital 
Isolates of Bactemides fragilis in Kuwait 
V.O. Rotimi, F. Bibi, W Jamal, E. Mokaddas. Department $ 
Microbiolon, Faulty $Medicine, Kuwait 
Objective: To evaluate the activities ofimipenem and meropenem (a 
newly registered antibiotic in Kuwait) in comparison to that ofamox- 
icillin/cladamc acid against hospital isolates of Bncteroidesfia@lis. 
Methods: The activities of imipenem and meropenem versus 
amoxicillin/clavulanic acid were evaluated against 98 s t r a i n s  of B.  
fiagilis isolated from 2 Kuwait hospitals. A 0.5 McFarland standard 
bacterial suspension, checked for actual C F U / d  of B.fia@lis, was in- 
oculated, using a 36-pin replicator, onto brucella agar supplemented 
with 5% lysed horse blood. The agar contained serial doubling dilu- 
tions of the various antibiotics with final concentrations of 0.03-64 
p g / d  ofeach antibiotic. The inoculated antibiotic-containing plates 
were incubated in anaerobic jars in an atmosphere of 10% COz and 
90% H 2  for 48 h. 
Results: The MICSO and MIC90 for the 98 isolates were as fol- 
lows: amoxicillin/clavulanic acid, 1 and 4 Fg/ml; imipenem, 0.5 and 
2 p g / d  and meropenem, 0.06 and 1 p g / d  respectively Both car- 
bapenems showed better activities than the amoxicillin/clavulanate; 
meropenem being superior in activity over all. However, using the 
criteria for interpretation recommended by NCCLS, 1993, all the 
isolates were susceptible to the anti-anaerobic agents. These MICs 
were far below the achievable serum levels for each antibiotic. 
Conclusion: The carbapenems and amoxicillin/clavulanic acid 
have excellent activities against B. fiagilis isolates from the 2 Kuwait 
hospitals. 
Ip6991 Comparative in Vitm Activities of Ceftibuten 
and other P-Lactam Antibiotics Against Hospital 
Pathogens 
T.K.’W. Ling, E.Y.M. Liu, A.EB. Cheng. Department of microbiology, 
Prince of Wales Hospital, Hong Kong, The Chinese University of Hong 
Kong, Hong Kong 
Objectives: To Study the in-vim activity of ceftibuten, a new oral 
third-generation cephalosporin in comparison with that of cefe- 
tamet, cefuroxime, cefaclor and amoxycillin in combination with 
clavulanate. 
Methods: The in-vim activities were studied against 829 
non-duplicate hospital isolates including E.  coli (81), K .  pneumoniae 
(75). Enterobarter spp. (89), Citrobarter spp. (35). Indole-positive Protars 
spp. (52), I! mirabilis (71), Salmonella spp. (92), Strep. pneumoniae ( l l l ) ,  
Streptocorn spp. (54), Moraxella cararrhulis (47), N. gononhoeae (35) and 
H. infuenzae (87). MIC of antimicrobial agents were determined by 
the agar ddution method and a multipoint inoculator was used to 
deliver lo4 colony forming unit per spot onto the agar plate. 
Results and Conclusions: Cefiibuten demonstrated excellent 
antimicrobial activities against most of the Enterobacteriaceae in- 
cluding Enterobocter spp. and Citrobarter spp. with MIC5o ranging h m  
t0.06 mg/l to 2 mgA. However this compound showed less activi- 
ties against streptococci with MIC90 = 128 mg/l. T h  agent was also 
active against M .  catarrhalis, with MIC9o = 4 mgA, and was highly 
active against H .  infuenrae and N. gononhoeae (MICw = 0.5 and 2 
mgA respectively). 
I P700 I Multicentre In Viro Comparison of Meropenem 
with Other Antibiotics Against Recent Isolates 
from Hospitalised Patients 
R. Frei for the Swiss in Vitm Study Group. Bacteriology Laboratory, 
Unimsity Clinics, Basel, Switzerland 
Objective: To evaluate the in v im activity of meropenem 
(MEM), imipenem (IMI), piperacillin/tazobactarn (?/T), amoxi- 
cd lm/c lavhc  acid (A/C) and ceftazidune (CAZ) on aerobic, non- 
replicate patients’ isolates in Switzerland. 
Method MICs were determined in 9 medical centres by usmg 
the E-test. 
Results: A total of 1824 isolates were tested. MIC9o s (mg/l) were 
as follows: 
____ ~~ ~_______ 
Orpmm(n) MEM IMI P/T AIC CAZ 
S. durn. metht.-susc. (159) 
Coag.-neg. staph.. ms (163) 
S. pncvmoniar (160) 
Entnwwur spp, (161) 
E. cob (175) 
Klrbsrrlla spp. (139) 
Rotcur mimbilir (87) 
M. mopgcmii (28) 
E n t n o b n  spp. (125) 
s m t i o  spp. (44) 
P llnugznoro (202) 
Adnetobm spp. (28) 
























8 > 128 









> 128 16 
> 128 8 
> 128 0.5 
> 128 16 
64 64 
2 0.25 
Conclusion: W h i l e  meropenem was more active than imipenem 
against virtually all Gram-negative bacilli, some Gram-positive or- 
ganisms were more susceptible to imipenem. 
I P701 I Comparative In Vitm Activity of Meropenem 
against 1798 Pseudomonas aetuginosa in a 
French Multicentre Study 
M.O. Husson’, H. Richet, Aubert, C. Cattoen, A. Chardon, 
V. Jarlier, D. Izard, E. Lecaillon, Melon, Morel, M.H. Nicolas. 
‘Laboratoire de Bacf&ologie-Hygibe, Fac. de Mbdecine, 1 place de 
Verdun, Lille 59045, France 
Objective: To evaluate the susceptibility of 1798 strains of Pseu- 
domonas aemginosa (PA) to meropenem (MER) isolated in 10 Mer- 
ent h n c h  hospitals. 
Methods: Comparative agents were ticarcillin (TIC), ticarcillin 
+ clavulanate (TCC), p iperach  (PIP), p iperacb  + tazobac- 
tam (PTZ), cefsulodin (CFS), cefepime (FEP), ceftazidime (CAZ), 
aztreonam (ATZ), imipenem (IP), gentamicin (GEN), tobramycin 
(TOB), netilmycin (NET), amikacin (AK), cipro5oxacine (CIP), fos- 
fomycin (FOS). The susceptibility to antibiotics was determined by 
the disc &sion method using the same lot of medium and corre- 
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sponding discs (Sanofi Diagnostics Pasteur), and by an agar dilution 
method when the strains were resistant to TIC. 
Results and discussion: MER was the most potent agent with 
a rate of susceptible strains of 89.3%. The proportion of sensitive 
strains for the remaining antibactenals was as follows: CAZ (87.2%), 
IP (85%), PTZ (84.7%). AK (82%), PIP (81.7%), ATZ (80.6%), FEP 
(77%), CFS (75.9%), TOB (72.3%), CIP (67.6%), TIC, (65.8%), 
TCC (63.6%), NET (58%). GEN (54%), and FOS (43%). At a break 
point of 4 mg/l, MER appeared active in vim against 83.1, 60.3, 
and 11.4% of clinical isolates of Pa that were resistant to TIC, to 
TIC and CAZ, or to IP respxtively. It showed an higher in&- 
sic activity with lower MICs than those of IF! Strains of serotype 
0 1 2  were highly resistant to antibiotics. Only MER, CAZ, and 
FOS were active with a proportion of sensitive strains of 70,72 and 
65%. 
I P702 1 In Viro Activities of 6 Extended Spectrum 
Beta-lactam Antibiotics Against Clinical 
Significant Gram-negative Bacteria 
I. Van haute, G. Verschraegen. University Hospital Gent, Belgium 
Objectives: To compare the susceptibility of cefpmme (CPO), ce- 
fepime (FEP), ceftazidime (CAZ), piperacillin-tazobactam (TZP), 
ticarciuln-clavulan~c acid (TCA) and amoxicillin-cla+c acid 
(AUG) against 145 Enterobacteriaceae and 101 non-fermenters. 
Methods: 246 consecutive signhcant gram-negative isolates were 
collected h m  intensive care, hematology or oncology patients. The 
strains were identified by conventional methods. The susceptibil- 
ity testing was performed on MuelIer-Hinton I1 agar with pa- 
per&& using the Stokes method, as well as the MIC value of the 
cephalosporins by E-test. 
Results. FEP and CPO were the most active antibiotics against 
all Enterobacteriaceae, followed by CAZ, TZP, TCA and AUG. At 
the break-point value of 8 mg/L, 99% of the isolates were inhib- 
ited by FEP and CPO versus 81% for CAZ. The 28 CAZ-resistant 
Enterobacteriaceae were still sensitive for FEP and CPO, except one 
st ra in .  The MIC50 of CPO and FEP was 0.064 mg/L and the 
MIC90 1 mg/L. For CAZ-resistant Enterobacteriaceae, which were 
still sensitive for CPO and FEP, the MIC50 and MIC90 were 0.75 
and 4 mg/L respectively In the group of the non-fermenters, espe- 
c d y  Pseudomonas spp, the susceptibility of CAZ 7 FEP z TZP =- 
CPO, while there was no difference in susceptibility of the antibi- 
otics against Acinetobacter spp. 
Conclusions: CPO and FEP have s& superior activity against 
Entembacteriaceae but their MIC value in the CAZ resistant p u p  is 
already hgher. In the group of non-fermenters, there is a 5% Mer- 
ence in susceptibility in favour of CAZ at susceptibility break-point 
of 8 mg/L. 
Antimicrobial Profile of Faropenem, a New Oral 
Penem 
A. Marchese, E.A. Debbia, A. Brysher', G.C. Schito. Institute .f 
Micro6iolofl, University of Getloa, Italy, h rotasel-Ucld Romainville, 
France 
The activity of faropenem, a new oral penem, was evaluated in com- 
parison with other drugs using NCCLS-guided MIC methodology, 
against 1456 aerobic and anaerobic bacterial isolates. The pathogens 
were: 503 S. pneumoniae 30 S. aureus, 30 Enterococd, 30 Strep- 
tococci, 310 H .  infuenzae, 63 M .  ratarrhalis, 30 N. gonorrhoeae, 30 
B. jagilis, 30 C. dlfFile and 280 Enterobarreriaceae. Among these, 100 
isolates were well characterized aminoglycoside-resistant (AG-R) or- 
ganisms and/or produced B-lactamases including extended-spectrum 
enzymes (ESBLs). Among the Pneumococci 29 displayed low or 
hgh level penidin resistance. Faropenem was the most potent agent 
against Streptococci (penidin resistant pneumococci included). It 
also behaved as the most active B-lactam against Entero6adm spp., K. 
pneumoniae, M .  morganii, B. j a g &  and C. dtjicile. Its potency was 
comparable to that of other B-lactams against S. a u m ,  S. marcescens, 
K .  oxytoca, €? mirabilis and M. catarrhalis. Faropenem showed an cx- 
cellent potency against E. coli, N. gonorrhoeae, Citrobacter spp and H. 
infuenzae while E.&ecium was resistant. Agamt ESBL producers and 
AG-R K. pneumoniae faropenem emerged as the most effective drug. 
Time-kill experiments were also performed with M .  catarrhah and 
H. injuenzae to explore the rate of killing of faropenem against these 
important respiratory pathogens. Faropenem displayed an excellent 
bactericidal effect (99.9% &g within 24 h at 2XMIC of the test 
organisms) against 6 H .  infuenzae (3 B-lactamase producers) and 6 
M .  catarrhalis (3 B-lactamase producers). These data suggest a poten- 
tial use of the new drug for the oral therapy of dections sustained by 
aerobic and anaerobic pathogens independently of their B-lactamase 
production or AG resistance. Peni&-resistant pneumococd, until 
now rehctory to oral cephalosporins, seem amenable to eradication 
by thls new penem. 
I P704 I Antipneumococcal Activii of Sanfetrinem, a 
New Oral Trinem, Compared to 11 Other Agents 
S.K. Spangler', M.R. Jacobs', PC. Appelbaum'. 'Med. Ch., 
Hershey, PA, USA, 'Case Westem Reserve Univ., Cleveland, OH, USA 
Objectives: To examine the antipneumococcal activity of san- 
fetrinem, a new oral trinem, compared to other oral and parented 
compounds. 
Methods: Agar ddution was used to test activity of sanfetrinem 
(GV 104326), a new oral trinem, peniciuln G, ampicillin, amoxi- 
ciuln, amoxicillin/clavulanate, cefpodoxime, loracarbef, levofloxacin, 
clarithmmycin, cefcrione, imipenem and vancomycin against 53 
penicillin susceptible (S), 84 intermediate (I) and 74 resistant (R) 
pneumococci isolated recently horn the U.S. Time-lulls were also 
performed on 3 S, 3 I and 3 R strains. 
Results: Agar dilution MICsopos (pg/ml) of the 21 1 strains were: 
DNK S I R Drug S I R 
PeniG 0.03/0.06 0.291 418 hncu 1/2 16/64 >64/>64 
S& 0.008/0.03 0.06/0.5 0.5/1 LemEo 1/2 1/2 2/2 
Ampicillin 0.03/0.12 0.5/2 418 Clarirhr 0.03/2 0.25/4 2/>64 
Amodcillin 0.03/0.06 0.25/1 418 Ccfrriu 0.008/0.12 0.25/0.5 112 
Amox/cLv 0.03/0.06 0.25/1 418 Imipcn 0.03/0.06 0.06/0.25 0.25/1 
C+~OX 0.03/0.2s 112 8/16 vmco 0.12/0.25 0.12/0.25 0.12/0.25 
Time-kills showed that all compounds yielded 99.9% killing of all 
strains after 24 h at the broth microdilution MIC. Kinetic patterns of 
all oral B-laaams, ceftriaxone and Mncomycin were similar relative 
to MIC, with 90% killing of a l l  strains first seen after 12 h. Killing 
by darithromycin was slightly slower and that by imipenem and 
levofloxacin slightly faster. K&ng patterns at 2 x MIC were similar 
to those at the MIC. 
Conclusions: Based on MICs and time-kills, sanfehinem was the 
most active of all oral agents tested. 
The Influence of Experimental Conditions on the 
In Vitm Activity of Sanfetrinem, a New Oral 
Trinem Antibiotic 
J. Lowther, I. Erbetti, L. Piccoli, E. Di Modugno. GZaxo Wellrome 
Research Centre, Krona, Italy 
Sanfetrinem is a new potent broad spectrum antibacterial agent be- 
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longing to the trinem dass of p-lactam antibiotics. Formulated as 
the hexed ester (sadetrinem cilexed), it has the potential to be 
used in the oral therapy of a range of community acquired infec- 
tions, particularly of the upper respiratory tract. The activity in vitro 
of sanfetrinem has been assessed under merent test conditions. 
MICs for a range of commonly occurring isolates were usually 
within one or two serial dilutions of the MIC obtained in MueIler 
Hinton meda, regardless of inoculum size, pH, incubation atmo- 
sphere, growth medium or presence of biological fluids. 
A study was performed to examine the effect of supplements &- 
quently used for the culture of Haemophilus spp. In common with 
carbapenem antibiotics, the presence of growth supplements con- 
taining cysteine antagonises the activity of sadetrinem. Haemophilus 
Test Medium as recommended by NCCLS should be used for testing 
this organism. 
Sanfetrinem solutions prepared in microbiological broth media 
and &ozen in microtitre plates, were shown to be stable at -80°C 
but not at -20°C. The lower storage temperature is essential i f b s  
technique is used for roudne MIC determinations of sanfetrinem. 
The results show that sanfetrinem can be expected to perform 
consistently in either agar or broth MIC tests under a wide range of 
Merent conditions. 
)p7061 Synergistic, Additive or Indifferent Effects of 
Sanfetrinem, a New Oral Trinem, in Combination 
with Other Antimicrobial Agents 
J. Lowther, I. Erbetd, D. Sabatini, E. Di Modugno. Glaxo Wellcome 
Research Centre, Vkrona, Italy 
Sanfetrinem is a new, potent broad spectrum antibacterial agent be- 
longing to the trinem class of 8-lactam antibiotics. Formulated as the 
hexed ester (sanfetrinem cilexetil), it has the potential to be used in 
oral therapy of a range of community acquired infections, particu- 
larly of the upper respiratory tract. Although the perceived cknical 
utility of sanfetrinem cilexetil is as a single agent, it is important 
to rule out antagonism with other antimicrobials. Sanfetrinem was 
tested using the checkerboard technique against representative bac- 
teria in combination with examples of other classes of antibacterial 
agents, antiviral and andfungal agents. Combination of sanfetrinem 
with amoxicillin/clavulanate, ciprofloxacin, vancomycin, gentamicin 
and memnidazole resulted in additive or indfferent effects. Only 
combination with chloramphenicol gave significant antagonism, a 
phenomenon which is well known for 8-lactams The antlfungal 
agents ketoconazole and amphotericin did not antagonise the activ- 
ity of sadetrinem, or vice versa. Likewise the antiviral agents, AZT 
and acyclovir, did not affect the activity of sanfetrinem. In a study 
combining sanfetrinem with the newer macrolides against respiratory 
tract pathogens, d y  indifferent or additive effects were shown. 
No instances of antagonism occurred. 
Sanfetrinem showed synergism against some MRSA and entero- 
cocci strains when combined with other anti-Gram positive agents. 
Overall, the combination of sadetrinem with other antimicrobial 
agents is primarily additive or indiEerent. No sigdcant cases of 
antagonism were seen. 
I P707 I Antibacterial Activity of Loracarbef Compared 
with Other Commonly Used Oral Antibiotics 
against Community-Acquired Pathogens 
A.M. Shibl. King Saud Univenify, Riyadh, Saudi Arabia 
Objectives: The activity of Loracarbef against 800 recent clinical 
isolates was compared to that of Cephalexin, Cefuroxjme, Amoxi- 
c h ,  Erythromycin and Amoxicilldclavulanate. 
Methods: The minimal inhibitory concentrations (MICs) were 
determined by an agar dilution method. 
Results: S. aureus, 5'. pneumoniae and S. pyogenes were all sus- 
ceptible to Loracarbef at MICs ranging firm 0.03 to 1 pg/ml. 
The MICsos of most of the other tested drugs were two-fold to 
four-fold higher against 8-lactamase producing strains of S. aureus 
than against non-producing strains. The MIC9o of Loracarbef was 
2 p g / d  against 8-lactamase producing and non-producing strains 
of H. infuenzae. Loracarbef resistance was not noted with s t r a i n s  of 
H. infuenzae that lacked #?-lactamase, Amoxich/Clavulanate and 
Cefuroxime showed good activity against H. infuenzae with MIC9os 
of 1-2 pg/ml. The MICgos of Loracarbef against E .  coli, Klebsiella 
species and P mirabilis were 1 p g / d  while those of the other drugs 
were 2 to > 128 pg/ml. 
Conclusions: The study indicated that Loracarbef offers advan- 
tages over the other study drugs for the treatment of community 
acquired pathogens that cause upper and lower respiratory tract in- 
fections, urinary tract mfections and infections of the skin and soft 
tissue. 
1 P708 I In Vitro Activity of Cefpirome against 
Streptococcus pneumoniae Strains with 
Decreased Susceptibility to Cefotaxime 
A. Fr&maux, G. Sissia, C. Spicq, P. Geslin. Centre National de 
Nf&ence du Pneumocoque, C H I C ,  Criteil, France 
During 1995, the French National Reference Center for Pneumo- 
cocci received 4965 strains of S. pneumoniae (SP). Cefotaxime (CTX) 
MIC, (mg/l) against these strains were: 50.25: n = 3049, 0.5: n 
= 497, 1: n = 1378, 2 2: n = 41. The objective of this study 
was to compare the in vim activity of cefpirome (CPO), p e n i c h  
(P), amoxicillin (AMX)  and cefepime (FEP) against a sample of S.  
pneumoniae (SP) strains with decreased susceptibhty to cefotaxime 
(CTX). One hundred and twenty strains were included in ths study. 
MIC, were determined by agar dilution method on Mueller Hinton 
medium supplemented with 5% horse blood 
CPO P AMX FEP 
0.5 (n = 26) 0.25/0.5 [0.25-0.5] 1/2 [0.12-21 1/1 [O.OLZ] 1/1 [OH11 
1 (n = 53) 0.5/1 [0.5-1] 2/4 [ I 4 1  2/2  ( 1 4 1  1/2 [I-21 
2 (n = 36) 1/1 [l-21 214 [ 1 4 ]  2/8 [l-161 212 [l-21 
4-€ (n = 5) - 11-21 - r2-41 - 12-16) - 12-41 
Whatever the level of susceptibility to CTX, CPO remains the 
most active compound. Even against highly resistant strains (CTX 
MIC, z 2 mg/l), CPO MIC, do not exceed 2 mg/l. These results 
confirm the good activity of CPO against SP, that may be of interest 
for the treatment of severe SP infections, especially those due to 
highly resistant strains. 
Susceptibility of 100 Strains of the 
Streptococcus millen Group against 16 
Cephalosporins, Both Old and New 
J.L. Gomez-Garces, B. Aracil, J.I. Alos. Seruicio de Microbiologia, 
Hospital de Mdsfoles, Madrid, Spain 
Although the S. millen group in udorrnly susceptible to penicillin 
G, its susceptibility top different cephalosporins varies slightly In this 
work we study the antimicrobial susceptibility of 100 clinically sig- 
nificant strains ofthe S. millen' group to 16 old an new cephalosporins 
using the agar dilution method according to NCCLS recommenda- 
tions. The results in mg/L were as follows: 
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MICSO MICw 5 (96) MIC50 MICm S (%) 
Ccphdom 0.5 0.5 100 Ccfvolin 0.5 1 100 
C e 6 c 1 or 2 8 100 Cc@rozil 0.5 1 100 
Cefimndole 0.25 0.25 100 Cefumnmc 0.25 0.5 100 
Ccfaxitin 4 8 100 Cehinox 8 > 8 63 
Cefowime 0.25 0.5 100 Ceftriaxonc 0.25 0.5 100 
ccfrwdunc 4 8 96 C e f n m h c  0.5 1 100 
ccfuome 4 8 8 Ccfpodmmc 0.25 0.5 100 
Ceftibutcn > 16 > 16 0 Cefepime 0.5 1 100 
In general first and second generation cephalosporins presented 
good activity, although in the case of cefaclor and cefoxitin MICso 
were near the breakpoint and 37% of the strains were resistant to 
cefminox. Third generation cephalosporins of parented administra- 
tion and cefepime showed excellent activity, although MICso of cef- 
tazidune was near the breakpoint. In the group of oral third gener- 
ation cephalosporins, all the shains were susceptible to cefpodoxime 
but the majority resistant to cefixime and all to cefcibuten. 
Glycopeptides for enterococci and other 
Gram-positive cocci II 
[p7101 WanA Glycopeptide Resistant Enterococci: 
Identical vanA Gene Cluster in Glycopeptide 
Resistant Enterococci from Man and 
Avoparcin-Exposed Pouttry 
H. Haaheim, G.S. Simonsen, 0. Olsvik, H. Kruse, A. Sundsfjord. 
Dept. OfMedical Microbiolofl, N-9037 University of Tromsr, Noway 
Objectives: Identification and characterization of the genes encod- 
ing hgh-level glycopeptide resistance in enterococci h m  Norwe- 
gian and Swedish humans and avoparcin-exposed Norwegian poul- 
try. 
Methods: High-level glycopeptide resistant enterococci (GRE) 
isolated h m  feces of avoparcin-exposed Norwegian poultry (N = 
l l ) ,  dinical human GRE-isolates h m  Swedish (N = 4) and Nonve- 
gian (N = 1) patients, and fivm feces of Norwegian poultry farmers 
(N = 4) were idenhfied by phenotypical methods and species spe- 
nhc ddl-PCR. Van resistance genes were analysed by specfic w&-, 
vanA-, and a long PCR covering the earlier described vanA gene 
cluster, Tn1546. 
Results: All poultry GRE-isolates were identified as E. faen'um. 
Identification of the 9 human GRE-isolates revealed five E. faecium, 
three E. duram and one E. hirae. All 20 isolates scored positive and 
negative in the vanA and vanB specific PCR, respectively. The long 
PCR, covering 10.414-bp of the 10.851-bp Tn1546, scored positive 
in 619 human-GRE and 8/11 poultry-GRE. Restriction hgment 
analysis, HincII/BinI-digests, revealed identical patterns. 
Conclusions: The identical restriction fi-agment length patterns 
of vanA gene clusters in human and poultry GRE-isolates indi- 
cate but do not document horizontal vanA gene transfer between 
avopanin-exposed poultry GRE and human fecal enterococci. 
I P711 I Strains of E. faeciurn Can Alter Their 
Glycopeptide Resistance Genotype During an 
Outbreak 
D. Morrison', P. Chadwick', B.D. Cookson', N. Woodford'. 
'MI, CPHL, London, 'PHL, Manchester, UK 
During an outbreak of VanB enterococci on a Leukaemia unit, E. 
faecium was lsolated fivm two patients (isolates D and C, respectively). 
These isolates were identical to the outbreak strain by Pulsed Field 
Gel Electrophoresis (PFGE) of SmaI-digested DNA and ribotyping 
(rRNA probing of the PFGE gels). However, both D and C were re- 
sistant to t e i c o p h  (VanA phenotype). An isolate indstinguishable 
h m  the outbreak s t r a i n  had been recovered fivm patient D seven 
months previously. Three plasmid profiles were observed; isolate C 
and the outbreak strain carried plasmids with the wnA and the vanB 
genes, respectively, while D carried both the vanA and wnB genes 
on two Merent plasmids. mnB transconjugants were obtained h m  
D and the outbreak strain,  indcating transferable uanB resistance. 
The uanB plasmids in these isolates had identical patterns following 
EcoRV digestion and an identical firagment (2.1 kb) hybridised with 
a vanB probe. The plasmid profiles of D and C Mered only by the 
absence of this uanB phsmid h m  C. These data suggest that during 
the outbreak, the predominant strain of E. fwcium, carrying a uanB 
plasmid, acquired a v a d  plasmid and other mobilizable plasmids, 
and subsequently lost its vanB plasmid. T h  study W t s  the re- 
markable ability of E. 4ecium to acquire and lose resistance genes. 
Resistance genotyping must be used in conjunction with PFGE to 
define fully the epidemiology of glycopeptide-resistant enterococci. 
I P712 I Development of Resistance to Glycopeptide in 
S. Stefani, M.L. Mezzatesta, M. Puntorieri, M. Santagati, 
B. Incalcaterra, C. Azzarelli, G. Nicoletti. University of Catania, Italy 
Objectives: Great discussion is related to the origin of glycopep- 
tide resistance: the result obtained at both the DNA and protein 
levels are in favour of an exogenous origin for high-level glycopep- 
tide resistance in Enterococci, but results obtained by Dukta-Malen 
et al. showed no homology between the vanA probe and genomic 
DNA of s a a i n s  producing teicoplanin, neither to the gene present 
in intrinsically resistant strains. No informations are available regard- 
ing vanB origin. These situation contrast with the stepwise changes 
in susceptibility to vancomycin of S. haemolyticuc which suggest an 
indigenous origin, by chromosomal mutation, for glycopeptide resis- 
tance. The selective pressure of the use of glycopeptides is associated 
with the emergence of transferable glycopeptide resistance in ente- 
rococci, but no informations are published on the possible changtng 
in some phenotype and genotype characteristics. 
Methods: The possible development of resistance was studied by 
serd  transfer, performed as follows: five serial aansfer with subin- 
hibitory concentrations of vancomycin and teicoplanm were fol- 
lowed by five transfer in antibiotic h e  medium. These serial trans- 
fers were repeated for six cycles at concentrations half of the MICs 
obtained in any previous passage. Cross induction of resistance was 
determined. To avoid any contamination, identification of variants 
were verified by API Strepto System (Bio Merieux), and, when nec- 
essary, by using PFGE analysis. Stability of the acquired induction 
was assessed by MIC determination after five daily passages every 
cycle of variants in antibiotic h e  medum. 
Results: Our results show that no mutants resistant to glycopep- 
tides could be selected after induction experiments: however some 
strains showed increased MIC values (9 strains showed MIC of 8 
mg/l to vancomycin after induction with Mncomycin it& no 
strains showed intermediate values of t e i c o p h  &er t e icophn 
induction). Studies are in progress to confirm the possible changes 
related to glycopeptide pressure on enterococcal strains. 
Enterococci 
